BlackRock
RLMD icon

BlackRock’s Relmada Therapeutics RLMD Stock Holding History

BlackRock’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.4M Buy
7,426,780
+6,137,230
+476% +$42.9M ﹤0.01% 2659
2026
Q1 		$8.98M Buy
1,289,550
+22,047
+2% +$104K ﹤0.01% 3573
2025
Q4 		$6.12M Buy
1,267,503
+759,503
+150% +$2.54M ﹤0.01% 3754
2025
Q3 		$1.02M Hold
508,000
– – ﹤0.01% 4279
2025
Q2 		$305K Sell
508,000
-58,905
-10% -$30.2K ﹤0.01% 4570
2025
Q1 		$153K Sell
566,905
-26,421
-4% -$8.76K ﹤0.01% 4657
2024
Q4 		$309K Buy
593,326
+25,446
+4% +$62.1K ﹤0.01% 4536
2024
Q3 		$1.84M Sell
567,880
-5,434
-0.9% -$17.6K ﹤0.01% 4023
2024
Q2 		$1.72M Sell
573,314
-4,874
-0.8% -$17.6K ﹤0.01% 4007
2024
Q1 		$2.69M Buy
578,188
+5,445
+1% +$26.2K ﹤0.01% 3894
2023
Q4 		$2.37M Sell
572,743
-1,364
-0.2% -$4.04K ﹤0.01% 3978
2023
Q3 		$1.72M Sell
574,107
-31,147
-5% -$92.5K ﹤0.01% 4057
2023
Q2 		$1.49M Sell
605,254
-1,233,163
-67% -$3.41M ﹤0.01% 4171
2023
Q1 		$4.15M Sell
1,838,417
-24,725
-1% -$85.3K ﹤0.01% 3711
2022
Q4 		$6.5M Sell
1,863,142
-290,186
-13% -$2.55M ﹤0.01% 3600
2022
Q3 		$79.7M Buy
2,153,328
+417
+0% +$11.6K ﹤0.01% 2114
2022
Q2 		$40.9M Buy
2,152,911
+200,103
+10% +$4.36M ﹤0.01% 2627
2022
Q1 		$52.7M Buy
1,952,808
+567,573
+41% +$11.7M ﹤0.01% 2553
2021
Q4 		$31.2M Buy
1,385,235
+174,994
+14% +$3.89M ﹤0.01% 2996
2021
Q3 		$31.7M Sell
1,210,241
-259,866
-18% -$6.96M ﹤0.01% 2967
2021
Q2 		$47.1M Sell
1,470,107
-18,068
-1% -$628K ﹤0.01% 2741
2021
Q1 		$52.4M Sell
1,488,175
-4,844
-0.3% -$169K ﹤0.01% 2583
2020
Q4 		$47.9M Buy
1,493,019
+280,318
+23% +$9.63M ﹤0.01% 2502
2020
Q3 		$45.6M Sell
1,212,701
-4,064
-0.3% -$157K ﹤0.01% 2359
2020
Q2 		$54.4M Buy
1,216,765
+738,752
+155% +$31.2M ﹤0.01% 2199
2020
Q1 		$16.3M Buy
478,013
+334,900
+234% +$13.5M ﹤0.01% 2711
2019
Q4 		$5.58M Buy
+143,113
New +$4.35M ﹤0.01% 3470

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock's RLMD Position: Q2 2026 in Review

BlackRock increased its Relmada Therapeutics (RLMD) stake by 476% in Q2 2026, buying an estimated $42.9M and bringing the position to 7,426,780 shares worth $51.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2659.

BlackRock first reported a position in RLMD in Q4 2019 and has held it in 27 quarters since. The position peaked at $79.7M in Q3 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • BlackRock held 7,426,780 shares of Relmada Therapeutics worth $51.4M as of Q2 2026.
  • BlackRock bought 6,137,230 Relmada Therapeutics shares in Q2 2026, an estimated $42.9M.
  • Relmada Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2659 holding.
  • BlackRock first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • BlackRock's Relmada Therapeutics position peaked at $79.7M in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.